{
  "test_submissions": [
    {
      "product_name": "Keytruda",
      "generic_name": "pembrolizumab",
      "indication": "Non-Small Cell Lung Cancer",
      "therapeutic_area": "Oncology",
      "development_stage": "Marketed",
      "nct_number": "NCT02220894",
      "sponsor": "Merck Sharp & Dohme",
      "line_of_therapy": "First-line",
      "patient_population": ["Advanced NSCLC", "PD-L1 positive"],
      "route_of_administration": "Intravenous",
      "submitter_name": "Test User",
      "submitter_email": "test@3cubed.com",
      "priority_level": "High"
    },
    {
      "product_name": "Ozempic",
      "generic_name": "semaglutide",
      "indication": "Type 2 Diabetes",
      "therapeutic_area": "Endocrinology",
      "development_stage": "Marketed",
      "nct_number": "NCT01720446",
      "sponsor": "Novo Nordisk",
      "line_of_therapy": "Second-line",
      "patient_population": ["Adults with T2D", "Inadequate glycemic control"],
      "route_of_administration": "Subcutaneous",
      "submitter_name": "Test User",
      "submitter_email": "test@3cubed.com",
      "priority_level": "High"
    },
    {
      "product_name": "Leqembi",
      "generic_name": "lecanemab",
      "indication": "Alzheimer's Disease",
      "therapeutic_area": "Neurology",
      "development_stage": "Recently Approved",
      "nct_number": "NCT01767311",
      "sponsor": "Eisai",
      "line_of_therapy": "First-line",
      "patient_population": ["Early Alzheimer's", "Mild cognitive impairment"],
      "route_of_administration": "Intravenous",
      "submitter_name": "Test User",
      "submitter_email": "test@3cubed.com",
      "priority_level": "High"
    },
    {
      "product_name": "TestDrug-001",
      "generic_name": "testmab",
      "indication": "Advanced Melanoma",
      "therapeutic_area": "Oncology",
      "development_stage": "Phase III",
      "nct_number": "NCT05123456",
      "sponsor": "Test Pharma Inc",
      "line_of_therapy": "Third-line",
      "patient_population": ["BRAF-mutant melanoma", "Previously treated"],
      "route_of_administration": "Intravenous",
      "submitter_name": "Test User",
      "submitter_email": "test@3cubed.com",
      "priority_level": "Medium"
    },
    {
      "product_name": "BioTest-202",
      "generic_name": "biotestuzumab",
      "indication": "Rheumatoid Arthritis",
      "therapeutic_area": "Rheumatology",
      "development_stage": "Phase II",
      "nct_number": "",
      "sponsor": "BioTest Therapeutics",
      "line_of_therapy": "Second-line",
      "patient_population": ["Moderate to severe RA", "TNF-inadequate responders"],
      "route_of_administration": "Subcutaneous",
      "submitter_name": "Test User",
      "submitter_email": "test@3cubed.com",
      "priority_level": "Low"
    }
  ]
}